Cannabis plant named ‘V1’

ABSTRACT

The unique annual herbaceous  Cannabis  plant variety  C. sativa  ‘V1’ is provided. The variety can be distinguished by its outstanding features of increased production of tetrahydrocannabivarin. The enhanced production of THCV inhibits the stimulation to eat normally associated with tetrahydrocannabinol.

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No.62/832,846 filed on Apr. 11, 2019, which is incorporated herein byreference in its entirety as though fully set forth herein.

BACKGROUND OF THE INVENTION Field of the Invention

The present invention relates to a new and distinct annual variety of C.sativa hybrid, which has been given the variety denomination of ‘V1’.‘V1’ is intended for use as medicinal herb for sale in Cannabisdispensaries and for use in the manufacture of medicinal andrecreational products.

Background of the Related Art

The genus Cannabis has been in use by humans for millennia, due to themultiplicity of its benefits to humans, including the considerable valueand utility of its fiber, the nutritional value of its seeds, and themedicinal value of its floral parts and products made from them.Currently the genus is under intense legal commercialization in theUnited States as industrial hemp for a variety of purposes includingbiodegradable plastics and building materials, clothing, paper, food,fuel and medicines.

Cannabidiol (CBD) extracted from Cannabis is widely used inover-the-counter medicines and topical treatments, and is also theactive ingredient in the FDA-approved drug Epidiolex. CBD is just one ofat least dozens—perhaps hundreds—of cannabinoids endogenous to Cannabis,tetrahydrocannabinol (THC) being the other cannabinoid that is mostwell-known. The cannabinoids as a group interact with the humanendocannabinoid receptors, which are distributed in the brain andthroughout the body. The study of the endocannabinoid system (ECS) inhumans and other mammals is an area of increasing interest and holdstremendous promise for the future of medicine. See, e.g., Russo (2019).Cannabis and Pain, Pain Medicine, 20(10): 1093/pm/pnz227; and Russo(2016). Clinical Endocannabinoid Deficiency Reconsidered: CurrentResearch Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel,and Other Treatment-Resistant Syndromes, Cannabis Cannabinoid Res. 1(1):154-165.

Non-hemp forms of Cannabis, frequently referred to as marijuana, havebeen legalized for medicinal use in many states and also forrecreational use (sometimes called “adult use”) in a growing number ofstates and including Alaska, California, Colorado, Illinois, Maine,Massachusetts, Nevada, Oregon, Vermont, and Washington, while remaining“fully illegal” in 11 states. It is also now permissible under the lawof at least 15 states for individuals to grow their own marijuanaplants, although in many of these states the home-grow is limited tosome sort of authorized medicinal use. It is expected that the wave oflegalization will continue to the point of some form of federallegalization or decriminalization.

Typically, marijuana products are available to users for purchase inspecialized “dispensaries” that offer dried flower, edibles, tinctures,extracts, and the like. In some cases, a unique or unusual chemicalprofile, or chemotype, is attractive not only for flower sales but alsofor use in the preparation of extracts and/or isolates and for themanufacture of a variety of products that possess characteristics of thechemotype.

SUMMARY OF THE INVENTION

The aim for the development of the new C. sativa variety, ‘V1’, was toproduce a variety featuring increased THCV levels relative to THClevels. The phytochemicals in Cannabis are known for their ability toaffect the human body. In live plants, THC is found in the form oftetrahydrocannabolic acid (THCA) that is converted to THC during dryingor under high heat. Similarly, THCV in live plants is in the form oftetrahydrocannabivarin carboxylic acid (THCVA). THC and THCV both bindto the cannabinoid receptors 1 (CB₁) and 2 (CB₂). Binding of CB₁ by itsendogenous ligands, anandamide or 2-arachidonoylglycerol, stimulatesfood intake (Silvestri, C., Di Marzo, V. 17 Cell Metabolism 475-490(2013)). THC acts as an agonist of CB₁ and stimulates appetite whileTHCV is a mild antagonist of CB₁ lessens sensations of hunger (Pertwee,R G. 153 British Journal of Pharmacology 199-215 (2008)). The ability ofTHCV to act as an antagonist of CB₁ has led to investigation of usingTHCV to treat metabolic syndrome and obesity (Riedel, G., et al., 156British Journal of Pharmacology 1154-1166 (2009)). Selection of avariety producing increased amounts of THCV allows optimized isolationof THCV which may be used in treatment of metabolic syndrome.

Embodiments of the invention relate to a seed from Cannabis plantdesignated ‘V1’ wherein a representative sample of seed of said planthas been deposited.

Some embodiments of the invention relate to a Cannabis plant, or plantpart, tissue, or cell thereof produced by growing the seed from Cannabisplant designated ‘V1’, or a descendant thereof.

In some embodiments, the Cannabis plant, or plant part, tissue, or cellthereof has a cannabinoid profile set forth in Table 1.

Some embodiments of the invention relate to the use of the plantdisclosed herein in a breeding program to produce Cannabis progeny witha cannabinoid profile set forth in Table 1 and genetic capacity toproduce the cannabinoid profile set forth in Table 1 in progeny thereof.

In some embodiments, the Cannabis plant part is selected from stems,trichomes, leaves, or flower buds.

In some embodiments, the invention relates to the Cannabis plantdescended from the plant, or plant part, tissue, cell or seed of ‘V1’,wherein the plant is a clonal descendent.

BRIEF DESCRIPTION OF PICTURES

The accompanying photographs show the typical appearance of the newvariety ‘V1’. The colors are as nearly true as is reasonably possible ina color representation of this type. Colors in the photographs maydiffer slightly from the color values cited in the detailed botanicaldescription which accurately describes the colors of the new plant.

FIG. 1 is a photograph of the new variety ‘V1’ at about age 12 weeks inits vegetative stage in Laytonville, Calif., U.S.A. in a 15-gallon pot.The photograph was taken in July 2018 and compares ‘V1’ with ‘V2’ (U.S.Provisional Patent No. 62/832,859). ‘V1’ is on the left of ‘V2’.

FIG. 2 is a photograph of the new variety ‘V1’ at about age 14 weeks inits vegetative stage in Laytonville, Calif., U.S.A. after pruning. Thephotograph was taken in July/August 2018 and compares ‘V1’, ‘V2’, and‘V3’ (U.S. Provisional Patent No. 62/832,863. ‘V1’ is in the center.‘V2’ is on the left of ‘V1’ and ‘V3’ is on the right of ‘V1’.

FIG. 3 is a photograph of the new variety ‘V1’ at about age 28-30 weeksin its vegetative stage in Laytonville, Calif., U.S.A. after pruning andin a 45-gallon pot.

FIG. 4 is a photograph of the new variety ‘V1’ at about age 28 weeks inits vegetative stage in Laytonville, Calif., U.S.A. in a 45-gallon pot.The photograph was taken in October 2018 and demonstrates that thevariety has a narrower leaf structure compared to other varieties.

DETAILED DESCRIPTION

The new C. sativa variety is a selection resulting from cross of afemale parent F12(P20)’ (unpatented) and a male parent ‘M31(P20)’(unpatented) in Laytonville, Calif., U.S.A since 2016. The new C. sativavariety ‘V1’ differs from the parental varieties, female F12(P20) andmale M31(P20), by having an increased production of THCV.

Plants of the new variety differ from typical C. sativa plants inincreased production of THCV compared to THC as determined bycannabinoid testing performed by an independent testing service. C.sativa ‘V1’ demonstrates elevated THCVA levels of up to 5.56%, and atotal THCV (THCV+THCVA) of up to 5.80% in tested flowers. C. sativa ‘V1’is a new variety with increased production of THCV compared to standardC. sativa varieties. C. sativa ‘V1’ has elevated levels of the uniqueterpene, farnesene (0.01-0.29% or higher). Farnesene is not normallyobserved in C. sativa and this may be a unique identifier of ‘V1’. Thisenhanced production of THCV makes ‘V1’ a variety of interest forproduction of medicinal products.

The selection has been propagated in Laytonville, Calif., U.S.A. Asexualreproduction of the new variety since 2016 has demonstrated that the newvariety reproduces true to type with all of the characteristics, asherein described, firmly fixed. Seeds representative of the ‘V1’ varietyhave also been produced. The seeds on deposit reflect the keycharacteristics of the ‘V1’ variety.

Some embodiments of the invention relate to a seed from a Cannabis plantdesignated ‘V1’ wherein a representative sample of seed of said planthas been deposited under accession number NCIMB 43867.

Some embodiments of the invention relate to a Cannabis plant, or plantpart, tissue, or cell thereof produced by growing the seed of ‘V1’, or adescendant thereof. Plant parts can include the embryo, shoot, root,stem, seed, stipule, leaf, petal, flower bud, flower, ovule, bract,trichome, branch, petiole, internode, bark, pubescence, tiller, rhizome,frond, blade, ovule, pollen, stamen, and the like.

The plants, or plant parts of the invention can display a cannabinoidprofile within the ranges set forth in Table 1, as defined herein. Theproductivity of any given cannabinoid and/or the amounts or ratios ofcannabinoids, terpenes, and other plant products can be, by nature,quite variable. The variability can be contributed to by weather,latitude, soil and feeding conditions, pathogens, and numerous otheragronomic, horticultural, and biological factors.

Some embodiments of the invention relate to methods of using the plantin a breeding program to produce Cannabis progeny including acannabinoid profile generally within the ranges as set forth in Table 1.Details of existing Cannabis plant varieties and breeding are describedin Potter et al. (2011, World Wide Weed: Global Trends in CannabisCultivation and Its Control), Holland (2010, The Pot Book: A CompleteGuide to Cannabis, Inner Traditions/Bear & Co, ISBN1594778981, 9781594778988), Green I (2009, The Cannabis Grow Bible: The Definitive Guide toGrowing Marijuana for Recreational and Medical Use, Green Candy Press,2009, ISBN 1931160589, 9781931160582), Green II (2005, The CannabisBreeder's Bible: The Definitive Guide to Marijuana Genetics, CannabisBotany and Creating Strains for the Seed Market, Green Candy Press,1931160279, 9781931160278), Starks (1990, Marijuana Chemistry Genetics,Processing & Potency, ISBN 0914171399, 9780914171393), Clarke (1981,Marijuana Botany, an Advanced Study: The Propagation and Breeding ofDistinctive Cannabis, Ronin Publishing, ISBN 091417178X, 9780914171782),Short (2004, Cultivating Exceptional Cannabis: An Expert Breeder SharesHis Secrets, ISBN 1936807122, 9781936807123), Cervantes (2004, MarijuanaHorticulture: The Indoor/Outdoor Medical Grower's Bible, Van PattenPublishing, ISBN 187882323X, 9781878823236), Franck et al. (1990,Marijuana Grower's Guide, Red Eye Press, ISBN 0929349016,9780929349015), Grotenhermen and Russo (2002, Cannabis and Cannabinoids:Pharmacology, Toxicology, and Therapeutic Potential, Psychology Press,ISBN 0789015080, 9780789015082), Rosenthal (2007, The Big Book of Buds:More Marijuana Varieties from the World's Great Seed Breeders, ISBN1936807068, 9781936807062), Clarke, RC (Cannabis: Evolution andEthnobotany 2013), King, J (Cannabible Vols 1-3, 2001-2006), and fourvolumes of Rosenthal's Big Book of Buds series (2001, 2004, 2007, and2011), each of which is herein incorporated by reference in its entiretyfor all purposes.

The present invention also relates to variants, mutants and minormodifications of the seeds, plant parts and/or whole plants of theCannabis plants of the present invention. Variants, mutants and minormodifications of the seeds, plants, plant parts, plant cells of thepresent invention can be generated by methods well known and availableto one skilled in the art, including but not limited to, mutagenesis(e.g., chemical mutagenesis, radiation mutagenesis, transposonmutagenesis, insertional mutagenesis, signature tagged mutagenesis,site-directed mutagenesis, and natural mutagenesis),knock-outs/knock-ins, antisense and RNA interference. For moreinformation of mutagenesis in plants, such as agents, protocols, seeAcquaah et al. (Principles of plant genetics and breeding,Wiley-Blackwell, 2007, ISBN 1405136464, 9781405136464,) which is hereinincorporated by reference in its entirety. Other kinds of modificationspracticed in the Cannabis industry, including but not limited tofeminization of seeds and/or day-length neutrality/autoflowering arealso within the scope of the invention and are within the level of skillin the art to execute.

The present invention also relates to a mutagenized population of theCannabis plants of the present invention, and methods of using suchpopulations. In some embodiments, the mutagenized population can be usedin screening for new Cannabis lines which comprises one or more or allof the morphological, physiological, biological, and/or chemicalcharacteristics of Cannabis plants of the present invention.

In some embodiments, the new Cannabis plants obtained from the screeningprocess comprise one or more or all of the morphological, physiological,biological, and/or chemical characteristics of Cannabis plants of thepresent invention, and one or more additional or different newmorphological, physiological, biological, and/or chemicalcharacteristic.

The present invention also provides any compositions or any productsmade from or isolated from the plants of the present invention. In someembodiments, the compositions/products comprise an extract of theplants. In some embodiments, the extract can contain a higher percentageof terpenes/terpenoids compared to extract isolated from a controlCannabis plant variety (e.g., an existing variety, such as arecreational Cannabis plant variety). In some embodiments, the inventionrelates to a smokable or edible product comprising the Cannabis plant,or plant part, tissue, cell, extract, or isolate.

The present invention provides methods of using the Cannabis plants orany parts, any compositions, or any chemicals derived from said plantsof the present invention.

In some embodiments, the plants of the present invention can be used toproduce new plant varieties. In some embodiments, the plants are used todevelop new varieties or hybrids with desired phenotypes or genotypes.

In some embodiments, selection methods, e.g., molecular marker assistedselection, can be combined with breeding methods to accelerate theprocess. Additional breeding methods known to those of ordinary skill inthe art include, e.g., methods discussed in Chahal and Gosal (Principlesand procedures of plant breeding: biotechnological and conventionalapproaches, CRC Press, 2002, ISBN 084931321X, 9780849313219), Taji etal. (In vitro plant breeding, Routledge, 2002, ISBN 156022908X,9781560229087), Richards (Plant breeding systems, Taylor & Francis US,1997, ISBN 0412574500, 9780412574504), Hayes (Methods of Plant Breeding,Publisher: READ BOOKS, 2007, ISBN1406737062, 9781406737066), each ofwhich is incorporated by reference in its entirety. The Cannabis genomehas been sequenced (Bakel et al., The draft genome and transcriptome ofCannabis sativa, Genome Biology, 12(10):R102, 2011). Molecular makersfor Cannabis plants are described in Datwyler et al. (Genetic variationin hemp and marijuana (Cannabis sativa L.) according to amplifiedfragment length polymorphisms, J Forensic Sci. 2006 March;51(2):371-5.), Pinarkara et al., (RAPD analysis of seized marijuana(Cannabis sativa L.) in Turkey, Electronic Journal of Biotechnology,12(1), 2009), Hakki et al., (Inter simple sequence repeats separateefficiently hemp from marijuana (Cannabis sativa L.), Electronic Journalof Biotechnology, 10(4), 2007), Datwyler et al., (Genetic Variation inHemp and Marijuana (Cannabis sativa L.) According to Amplified FragmentLength Polymorphisms, J Forensic Sci, March 2006, 51(2):371-375),Gilmore et al. (Isolation of microsatellite markers in Cannabis sativaL. (marijuana), Molecular Ecology Notes, 3(1): 105-107, March 2003),Pacifico et al., (Genetics and marker assisted selection of chemotype inCannabis sativa L.), Molecular Breeding (2006) 17:257-268), and Mendozaet al., (Genetic individualization of Cannabis sativa by a short tandemrepeat multiplex system, Anal Bioanal Chem (2009) 393:719-726), each ofwhich is herein incorporated by reference in its entirety.

In some embodiments, the Cannabis plant, or plant part, tissue, or cellof ‘V1’ comprises a cannabinoid profile as set forth in Table 1.

TABLE 1 Exemplary Profiles of Key Cannabinoids. Percent Percent PercentPercent Percent d9-THC 0.00 0.02 0.15 0.29 0.35 THCA 0.58 1.16 2.89 5.336.40 Total THC* 0.51 1.04 2.69 4.96 5.95 THCV 0.00 0.02 0.13 0.24 0.29THCVA 1.00 1.71 3.56 5.56 6.67 THCV + THCVA 1.00 1.73 3.69 5.80 6.96CBG + CBGA 0.00 0.12 0.27 0.54 0.64 CBCA 0.00 0.07 0.16 0.32 0.38 Total1.75 2.99 6.89 11.75 14.25 Cannabinoid THCV/THC (%) 196 166 137 116 117THCV/Total 57 58 54 49 49 Cannabinoid (%) *Total THC = (THCA * 0.877) +THC (i.e. delta 9 THC) + delta 8 THC

In some embodiments, the invention relates to a Cannabis cloneregenerated from the Cannabis plant of descended from the plant, orplant part, tissue, cell or seed of ‘V1’ wherein the plant is a clonaldescendent.

In some embodiments, the invention relates to a method of producing anF1 Cannabis seed, wherein the method includes crossing the plant with adifferent Cannabis plant and harvesting the resultant F1 Cannabis seed.In some embodiments, the invention relates to the F1 hybrid Cannabisseed produced by this method. In some embodiments, the invention relatesto a F1 hybrid Cannabis plant produced by growing the F1 hybrid Cannabisseed. In some embodiments, the invention relates to a Cannabis cloneregenerated from the F1 hybrid Cannabis plant. In some embodiments, theinvention relates to a smokable or edible product comprising Cannabistissue from the F1 hybrid Cannabis plant.

The following detailed description sets forth the distinctivecharacteristics of ‘V1’. Applicant is prepared to make a deposit ofseeds or plant tissue.

Type: Herbaceous tap-rooted annual.

Classification:

-   -   a. Family—Cannabaeae.    -   b. Genus—Cannabis.    -   c. Species—sativa.    -   d. Common Name—marijuana.

Parentage: Female Parent—‘F12(P20)’; Male Parent—‘M31(P20)’

Market Class: A medicinal herb intended for use as medical oil, andmedicinal herb for sale in Cannabis dispensaries ‘and for use in themanufacture of medicinal and recreational products.

Genetic Analysis

A genetic analysis was conducted on a tissue sample of ‘V1’. The resultsof the analysis are as follows:

A. Closest known relatives in reference genetic database:

‘V2’ aka Masai, which is the subject matter of provisional patentapplication 62/832,859, filed on Apr. 11, 2019, entitled “CANNABIS PLANTNAMED ‘V2’”, as well as applications for plant patent and utility patentclaiming priority therefrom.

‘V3’ aka Reet Petit, which is the subject matter of provisional patentapplication 62/832,863, filed on Apr. 11, 2019, entitled “CANNABIS PLANTNAMED ‘V3’”, as well as applications for plant patent and utility patentclaiming priority therefrom.

B. Population Profile:

‘V1’ was indicated to have genetic heritage similar to varieties in“Landrace” subpopulations with minor similarities to “Skunk” and “CBD”subpopulations.

C. Genotypic Combination Analysis

‘V1’ was found to have a genotypic combination that would be classifiedas borderline between “common” and “uncommon.”

D. Genetic Variation (Heterozygosity) Analysis

‘V1’ was found to have a low level of heterozygosity as compared withother varieties in the reference database.

Deposit Information

A seed sample of this invention has been deposited with an InternationalDepositary Authority as established under the Budapest Treaty accordingto 37 CFR 1.803(a)(l), at the National Collections of Industrial, Foodand Marine Bacteria Ltd. (NCIMB) in Aberdeen Scotland under NCIMB No.43867.

To satisfy the enablement requirements of 35 U.S.C. 112, and to certifythat the deposit of the Cannabis varieties of the present inventionmeets the criteria set forth in 37 CFR 1.801-1.809 and Manual of PatentExamining Procedure (MPEP) 2402-2411. 05, Applicant(s) hereby makes thefollowing statements regarding the deposited Cannabis variety: If thedeposit is made under the terms of the Budapest Treaty, the instantinvention will be irrevocably and without restriction released to thepublic upon the granting of a patent. If the deposit is made not underthe terms of the Budapest Treaty, Applicant(s) provides assurance ofcompliance by the following statements:

1. During the pendency of this application, access to the invention willbe afforded to the Commissioner upon request;

2. All restrictions on availability to the public will be irrevocablyremoved upon granting of the patent under conditions specified in 37 CFR1.808;

3. The deposit will be maintained in a public repository for a period of30 years or 5 years after the last request or for the effective life ofthe patent, whichever is longer;

4. A test of the viability of the biological material at the time ofdeposit will be conducted by the public depository under 37 CFR 1.807;and

5. The deposit will be replaced if it should ever become unavailable.

Access to this deposit will be available during the pendency of thisapplication to persons determined by the Commissioner of Patents andTrademarks to be entitled thereto under 37 C.F.R. § 1.14 and 35 U.S.C. §122. Upon granting of any claims in this application, all restrictionson the availability to the public of the variety will be irrevocably andwithout restriction or condition removed by affording access to adeposit of the tissue sample of the same variety with the depository.

The invention claimed is:
 1. A seed from Cannabis plant designated ‘V1’wherein a representative sample of seed of said plant has been depositedunder accession number NCIMB 43867; wherein flower produced fromCannabis plant, or plant part, tissue, or cell thereof comprises acannabinoid profile of: a. d9-THC between 0%-0.35%; b. THCA between0.58%-6.40%; c. Total THC between 0.51%-5.95%; d. THCV between 0%-0.29%;e. THCVA between 1%-6.67%; f. THCV+THCVA between 1%-6.96%; g. CBG+CBGAbetween 0%-0.64%; h. CBCA between 0%-0.38%; i. Total cannabinoid between1.75%-14.25%; j. THCV/THC between 196%-117%; and k. THCV/Totalcannabinoid between 57%-49%.
 2. A Cannabis plant, or plant part, tissue,or cell thereof produced by growing the seed of claim 1, or a descendantthereof; wherein flower produced from Cannabis plant, or plant part,tissue, or cell thereof comprises a cannabinoid profile of: a. d9-THCbetween 0%-0.35%; b. THCA between 0.58%-6.40%; c. Total THC between0.51%-5.95%; d. THCV between 0%-0.29%; e. THCVA between 1%-6.67%; f.THCV+THCVA between 1%-6.96%; g. CBG+CBGA between 0%-0.64%; h. CBCAbetween 0%-0.38%; i. Total cannabinoid between 1.75%-14.25%; j. THCV/THCbetween 196%-117%; and k. THCV/Total cannabinoid between 57%-49%.
 3. TheCannabis plant, or plant part, tissue, or cell thereof of claim 2,wherein flower produced from the plant comprises a cannabinoid profileof: a. d9-THC between 0%-0.35%; b. THCA between 0.58%-6.40%; c. TotalTHC between 0.51%-5.95%; d. THCV between 0%-0.29%; e. THCVA between1%-6.67%; f. THCV+THCVA between 1%-6.96%; g. CBG+CBGA between 0%-0.64%;h. CBCA between 0%-0.38%; i. Total cannabinoid between 1.75%-14.25%; j.THCV/THC between 196%-117%; and k. THCV/Total cannabinoid between57%-49%.
 4. The Cannabis plant part of claim 2, wherein said plant partis selected from the group consisting of: stems, trichomes, leaves, andflower buds.
 5. The Cannabis plant descended from the plant, or plantpart, tissue, cell or seed of claim 2, wherein the plant is a clonaldescendent.
 6. A method of breeding a Cannabis plant, or plant part,tissue, or cell thereof, wherein the plant, plant part, tissue, or cellis produced by growing a seed or clone from: a. a Cannabis plantdesignated ‘V1’ wherein a representative sample of seed of said planthas been deposited under accession number NCIMB 43867; or b. adescendant of the Cannabis plant designated ‘V1’ wherein the plantcomprises a cannabinoid profile of: a. d9-THC between 0%-0.35%; b. THCAbetween 0.58%-6.40%; c. Total THC between 0.51%-5.95%; d. THCV between0%-0.29%; e. THCVA between 1%-6.67%; f. THCV+THCVA between 1%-6.96%; g.CBG+CBGA between 0%-0.64%; h. CBCA between 0%-0.38%; i. Totalcannabinoid between 1.75%-14.25%; j. THCV/THC between 196%-117%; and k.THCV/total cannabinoid between 57%-49%; and wherein the method comprisesproviding the plant as at least one parent in a breeding program andselecting progeny displaying the cannabinoid profile of: a. d9-THCbetween 0%-0.35%; b. THCA between 0.58%-6.40%; c. Total THC between0.51%-5.95%; d. THCV between 0%-0.29%; e. THCVA between 1%-6.67%; f.THCV+THCVA between 1%-6.96%; g. CBG+CBGA between 0%-0.64%; h. CBCAbetween 0%-0.38%; i. Total cannabinoid between 1.75%-14.25%; j. THCV/THCbetween 196%-117%; and k. THCV/total cannabinoid between 57%-49%.